ADVERTISEMENT

Conference Report

ASCO 2022 – A novel option for K-RAS wild type late-stage pancreatic cancer

Elena Riboldi — Agenzia Zoe   |   08 June 2022

Takeaway

  • The combination of nimotuzumab and gemcitabine prolonged survival (10.9 vs 8.5 months) In K-RAS wild-type locally advanced or metastatic pancreatic cancer (PC), compared to gemcitabine alone, particularly in patients without a surgical history.

 

Why this matters

  • No effective treatments exist for advanced pancreatic adenocarcinoma.
  • Nimotuzumab is a humanised...

          

November Challenge

Ends in 1d 7h
left
right

Topic Challenges

left
right